Toulouse, France & Ann Arbor, Michigan, February 10, 2009 - Cerenis Therapeutics SA (Cerenis), a privately held pharmaceutical company, today announced that it has received a €2.5 million investment to finance ongoing clinical development of its portfolio of HDL-related products for the treatment of cardiovascular and metabolic diseases. The funds were granted by OSEO, a French public holding company that provides financial support to promising French companies.
